San Soohoo
YOU?
Author Swipe
View article: Supplementary Figure Legends 1-2 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
Supplementary Figure Legends 1-2 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival Open
PDF file - 70K
View article: Data from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
Data from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival Open
Up to 50% of epithelial ovarian cancers (EOC) display defects in the homologous recombination (HR) pathway. We sought to determine the ramifications of the homologous recombination–deficient (HRD) status on the clinicopathologic features, …
View article: Data from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
Data from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival Open
Up to 50% of epithelial ovarian cancers (EOC) display defects in the homologous recombination (HR) pathway. We sought to determine the ramifications of the homologous recombination–deficient (HRD) status on the clinicopathologic features, …
View article: Supplementary Figure Legends 1-2 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
Supplementary Figure Legends 1-2 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival Open
PDF file - 70K
View article: Supplementary Figure 1 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
Supplementary Figure 1 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival Open
PDF file - 103K, HR status and correlation with ex vivo cytotoxicity to PARP inhibitors. A, schema outlining study demontrating tight correlation between HR deficiency and sensitivity to PARP inhibitor for both epithelial EOCs and other HR…
View article: Supplementary Figure 2 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
Supplementary Figure 2 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival Open
PDF file - 62K, RAD51 foci and ex vivo cytotocicity in HR competent and HR deficient primary cultures A. Box plot showing cytotoxicity to 10 muM rucaparib B. Box plot showing RAD51 foci formation after 24 hr exposure to rucaparib or hydrox…
View article: Supplementary Figure 1 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
Supplementary Figure 1 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival Open
PDF file - 103K, HR status and correlation with ex vivo cytotoxicity to PARP inhibitors. A, schema outlining study demontrating tight correlation between HR deficiency and sensitivity to PARP inhibitor for both epithelial EOCs and other HR…
View article: Supplementary Figure 2 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
Supplementary Figure 2 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival Open
PDF file - 62K, RAD51 foci and ex vivo cytotocicity in HR competent and HR deficient primary cultures A. Box plot showing cytotoxicity to 10 muM rucaparib B. Box plot showing RAD51 foci formation after 24 hr exposure to rucaparib or hydrox…